O. Seitz et al.
6H; 2N+CH3), 3.99 (m, 2H; 2H3’), 4.44 (m, 8H; 4Bn-CH2), 4.94 (m,
1H; H1’), 5.10 (m, 1H; H1’), 6.61 (s, 2H; 2-CH=), 7.02–7.62 (m,
40H), 7.88 (m, 4H; 4Ts-H), 8.57 (m, 3H; 3TO-H), 8.80 ppm (m, 1H;
1TO-H); 13C NMR (75 MHz, CDCl3, 2 diastereomers): d=21.2 (2Ts-
CH3), 34.1 (C4a’), 34.2 (2CH3), 34.2 (C4a’), 37.4 (C2’), 38.4 (C2’), 44.5
(C4’), 44.7 (C4’), 60.4 (C1’), 61.5 (C1’), 71.0 (CH2), 71.1 (CH2), 71.5
(C6’), 71.6 (C6’), 73.1 (CH2), 73.2 (CH2), 79.6 (C3’), 81.0 (C3’), 88.5
(-CH=), 88.6 (-CH=), 108.7 (TO-ArCH), 109.5 (TO-ArCH), 111.8 (2TO-
ArCH), 115.9 (1TO-ArCH), 116.9 (1TO-ArCH), 121.9 (1TO-ArCH),
122.0 (1TO-ArCH), 123.9 (1TO-ArCH), 124.0 (1TO-ArCH), 124.2
(1TO-ArCq), 124.3 (1TO-ArCq), 124.5 (2TO-ArC’q), 126.1 (4Ts-ArCH),
126.2 (1TO-ArCH), 126.4 (1TO-ArCH), 126.6 (1TO-ArCH), 126.8
(1TO-ArCH), 127.1 (1TO-ArCH), 127.5 (2TO-ArCH), 127.6 (4Ts-ArCH,
4Bn-ArCH), 127.6 (4Bn-ArCH), 128.1 (TO-ArCH), 128.2 (2Bn-ArCH),
128.3 (2Bn-ArCH), 128.3 (4Bn-ArCH), 128.4 (4Bn-ArCH), 131.1 (1TO-
ArCH), 132.5 (1TO-ArCH), 137.1 (Bn-ArCq), 137.4 (Bn-ArCq) 137.9
(Bn-ArCq), 138.1 (2TO-ArCq), 138.2 (Bn-ArCq), 138.6 (2Ts-ArCH),
139.9 (1TO-ArCq), 140.0 (1TO-ArCq), 140.3 (1TO-ArCH), 140.4 (1TO-
ArCH), 139.9 (2TO-ArCq), 140.0 (2TO-ArCq), 140.4 (1TO-ArCH), 140.3
(1TO-ArCH), 144.7 (2Ts-ArCH), 148.2 (1TO-ArCq), 148.3 (1TO-ArCq),
159.5 (1TO-ArCq), 159.6 ppm (1TO-ArCq); HRMS (ESI): m/z calcd:
585.2570 [C38H37N2O2S]+, found: 585.2568.
H4’), 2.63 (m, 1H; H4a’b), 3.22 (m, 2H; H5’a, H5’b), 3.72 (s, 6H;
2DMT-OCH3), 3.80 (s, 3H; TO-H18), 4.32 (m, 1H; H3’), 5.32 (m, 1H;
H1’), 6.63 (s, 2H; TO-H10), 6:84 (m, 4H; 4DMT-ArH), 7.18 (m, 1H;
TO-H2), 7.23 (m, 1H; DMT-ArH), 7.30 (m, 6H; 6DMT-ArH), 7.34 (m,
1H; TO-H14), 7.43 (m, 3H; TO-H16, 2DMT-ArH), 7.51 (m, 1H; TO-
H15), 7.66 (m, 1H; TO-H6), 7.78 (m, 1H; TO-H13), 7.87 (m, 1H; TO-
H7), 7.98 (m, 1H; TO-H8), 8.27 (m, 1H; TO-H1), 8.48 ppm (m, 1H;
TO-H5); 13C NMR (100 MHz, CD3CN): d=34.5 (TO-H18), 35.2 (C4a’),
41.1 (C2’), 48.0 (C4’), 55.8 (2DMT-OCH3), 61.0 (C1’), 64.5 (C5’), 73.0
(C3’), 86.9 (DMT-Cq), 88.8 (TO-C10), 109.3 (TO-C2), 113.4 (TO-C16),
114.0 (2DMT-ArCH), 114.0 (2DMT-ArCH), 118.7 (TO-C8), 123.4 (TO-
C13), 125.1 (TO-C12), 125.4 (TO-C4), 125.5 (TO-C14), 126.2 (TO-C5),
127.7 (TO-C6), 127.8 (DMT-ArCH), 128.8 (2DMT-ArCH), 129.0 (2DMT-
ArCH), 129.1 (TO-C15), 130.9 (2DMT-ArCH), 130.9 (2DMT-ArCH),
134.1 (TO-C7), 137.1 (DMT-ArCq), 137.2 (DMT-ArCq), 139.0 (TO-C9),
140.2 (TO-C1), 141.4 (1TO-C17), 146.1 (DMT-ArCq), 149.5 (TO-C3),
159.5 (2DMT-ArCq), 161.3 ppm (TO-C11); HRMS (ESI): m/z calcd:
707.2938 [C45H43N2O4S]+, found: 707.2928.
4a’-Carba-a-(d)-5’-DMT-2’-deoxyribofuranose(TO) (5a): 1H NMR
(400 MHz, CD3CN): d=2.05 (m, 1H; H2’a), 2.19 (m, 2H; H4a’a,
H4a’b), 2.39 (m, 1H; H4’), 2.61 (m, 1H; H2’b), 3.18 (m, 2H; H5’a,
H5’b), 3.76 (s, 3H; TO-H18), 3.77 (s, 6H; 2DMT-OCH3), 4.28 (m, 1H;
H3’), 5.19 (m, 1H; H1’), 6.56 (s, 2H; TO-H10), 6:89 (m, 4H; 4DMT-
ArH), 7.21 (m, 1H; TO-H2), 7.27 (m, 2H; DMT-ArH, TO-H14), 7.35
(7H, m, 6DMT-ArH, TO-H16), 7.47 (m, 3H; TO-H15, 2DMT-ArH), 7.61
(m, 1H; TO-H6), 7.71 (m, 1H; TO-H13), 7.78 (m, 1H; TO-H7), 7.84
(m, 1H; TO-H8), 8.42 (m, 1H; TO-H5), 8.57 ppm (m, 1H; TO-H1);
13C NMR (100 MHz, CD3CN): d=34.4 (TO-C18), 35.5 (C4a’), 41.5
(C2’), 48.6 (C4’), 55.9 (2DMT-OCH3), 61.9 (C1’), 65.1 (C5’), 74.3 (C3’),
86.9 (DMT-Cq), 88.6 (TO-C10), 109.3 (TO-C2), 113.3 (TO-C16), 114.0
(4DMT-ArCH), 118.5 (TO-C8), 123.3 (TO-C13), 125.1 (TO-C12), 125.4
(TO-C4), 125.4 (TO-C14), 126.2 (TO-C5), 127.5 (TO-C6), 127.8 (DMT-
ArCH), 128.8 (2DMT-ArCH), 129.0 (2DMT-ArCH), 129.0 (TO-C15),
131.0 (4DMT-ArCH), 133.9 (TO-C7), 137.1 (DMT-ArCq), 137.1 (DMT-
ArCq), 138.9 (TO-C9), 141.3 (1TO-C17), 141.4 (TO-C1), 146.3 (DMT-
ArCq), 149.4 (TO-C3), 159.6 (2DMT-ArCq), 161.1 ppm (TO-C11);
HRMS (ESI): m/z calcd: 707.2938 [C45H43N2O4S]+, found: 707.2930.
4a’-Carba-a/b-(d)-2’-deoxyribofuranose(TO) (4): Under argon,
BBr3 (2.61 g, 1.02 mL, 10.4 mmol) was added dropwise to a cooled
(08C) solution of 3 (1.58 g, 2.09 mmol) in dry CH2Cl2 (60 mL). Com-
plete addition resulted in
a colorless suspension. Saturated
NaHCO3 (aq.) solution (150 mL) was added after 10 min. After
30 min the precipitate was collected, dried under reduced pressure
to give a red powder, which was used without further purification.
Rf =0.15 (CH2Cl2/MeOH/NEt3 90:10:0.1, v/v/v); 1H NMR (300 MHz,
[D6]DMSO, 2 diastereomers in 1:1.5 ratio): d=1.73 (m, 1H), 2.09 (m,
4H), 2.26 (m, 4H) 2.57 (m, 1H), 3.52 (m, 4H; 2H5’a, 2H5’b), 3.96 (s,
6H; 2CH3), 4.12 (m, 2H; 2H3’), 5.45 (m, 2H; 2H1’), 6.82 (s, 2H; 2CH),
7.32 (m, 4H; 4TO-H), 7.53 (m, 2H; 2TO-H), 7.70 (m, 4H; 4TO-H),
7.98 (m, 4H; 4TO-H), 8.21 (m, 2H; 2TO-H), 8.69 (m, 1H; TO-H), 8.75
(m, 2H; TO-H), 8.84 ppm (m, 1H; TO-H); 13C NMR (75 MHz,
[D6]DMSO, 2 diastereomers): d=33.8 (N+-CH3), 33.8 (N+-CH3), 34.0
(2C4a’), 40.2 (C2’), 40.6 (C2’), 48.8 (C4’), 49.3 (C4’), 59.8 (C1’), 60.4
(C1’), 61.8 (C5’), 61.9 (C5’), 70.9 (C3’), 71.9 (C3’), 87.8 (TO-CH=), 87.9
(TO-CH=), 108.1 (2TO-ArCH), 112.8 (1TO-ArCH), 114.0 112.8 (1TO-
ArCH), 117.8 (1TO-ArCH), 117.9 (1TO-ArCH), 122.7 (1TO-ArCH),
122.8 (1TO-ArCH), 123.7 (2TO-ArCq), 124.1 (1TO-ArCq), 124.1 (1TO-
ArCq), 124.2 (1TO-ArCH), 124.3 (1TO-ArCH), 125.7 (2TO-ArCH),
126.6 (1TO-ArCH), 126.6 (1TO-ArCH), 128.0 (2TO-ArCH), 133.0
(1TO-ArCH), 133.1 (1TO-ArCH), 137.5 (1TO-ArCq), 137.7 (1TO-ArCq),
140.1 (1TO-ArCH), 140.2 (2TO-ArCq), 140.9 (1TO-ArCH), 147.9 (1TO-
ArCq), 147.9 (1TO-ArCq), 159.6 (1TO-ArCq), 159.7 ppm (1TO-ArCq);
(ESI): m/z calcd: 405.1631 [C24H25N2O2S]+, found: 405.1628.
Preparation of phosphoramidites: Nucleoside (0.5 mmol) and 2-
cyanoethyl N,N-diisopropylchlorophosphoramidite (1.25 mmol,
296 mg, 279 mL) were added to a solution of freshly distilled
EtNiPr2 (2.5 mmol, 323 mg, 413 mL) in dry CH2Cl2 (10 mL). After 1 h
of stirring at room temperature the reaction was quenched by ad-
dition of saturated NaHCO3 (aq.). The organic layer was separated
and washed twice with saturated NaHCO3 (aq.), dried over MgSO4,
and filtered. The filtrate was collected, and the volatiles were re-
moved at reduced pressure. The crude product was dissolved in
dry CH3CN to a concentration of 0.1m and transferred to an ABI-
style reagent bottle for subsequent use in DNA synthesis.
4a’-Carba-a/b-(d)-5’-DMT-2’-deoxyribofuranose(TO) (5b/a): KPF6
(769 mg, 4.18 mmol) was added to a suspension of compound 4
(1.58 g, 2.09 mmol) in dry pyridine (100 mL) under argon. The
turbid solution became clear, and EtNiPr2 (2.70 g, 20.9 mmol,
3.45 mL) and DMTrCl (3.40 g, 10.0 mmol) were added. After 16 h
the mixture was filtered. The filtrate was concentrated. The residue
was dissolved in CH2Cl2, washed three times with saturated
NaHCO3 (aq.), dried (MgSO4), filtered, and concentrated. The resi-
due was purified by flash column chromatography in order to sep-
arate diastereomers, which were obtained as red solids (5b,
906 mg, 1.06 mmol, 51%; 5a, 604 mg, 0.71 mmol, 34%). Rf =0.80
(CH2Cl2/MeOH/NEt3 90:10:0.1, v/v/v).
DNA synthesis, work-up, and purification: The DNA FIT probes
were assembled by using a model 3400 synthesizer (Applied Bio-
systems) and by the phosphoramidite method (above). CPGs
(1 mmol, pore size 500 ꢂ) were purchased from Proligo (Sigma Al-
drich) and Link Technologies (Bellshill, UK), and DNA synthesis
reagents (dry CH3CN, trichloroacetic acid (3% in CH2Cl2), acetic an-
hydride in 2,6-lutidin/THF (1:1:8), 1-methylimidazole (16% in THF),
and iodine in water/pyridine/THF (3:2:20:75)) were purchased from
Roth or Link Technologies. The phosphoramidites dT, dABz, dCBz,
and dGDMF (0.1m) were used in dry CH3CN. Activator (5-benzylmer-
capto-1H-tetrazole (BMT)) was purchased from emp Biotech (Berlin,
Germany) and used as a 0.25m solution in dry CH3CN. The synthe-
sized phosphoramidites were used at 0.1m in dry CH3CN. The qual-
ity of each coupling step was monitored by measuring the conduc-
4a’-Carba-b-(d)-5’-DMT-2’-deoxyribofuranose(TO) (5b): 1H NMR
(400 MHz, CD3CN): d=1.67 (m, 1H; H4a’a), 2.29 (m, 3H; H2’a, H2’b,
&8
&
ꢀ 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ChemBioChem 0000, 00, 1 – 11
ÝÝ
These are not the final page numbers!